Hyperion Therapeutics Inc.'s (NASDAQ: HPTX) new drug to treat urea cycle disorders (UCDs) has won approval from the U.S. health regulators. The U.S. Food and Drug Administration (FDA) cleared Ravicti (glycerol phenylbutyrate) for the chronic management of some UCDs in patients ages 2 years and older. [More...]